Evidence map›Paper›PMID 41395317›Full record

ArticleIJTLD open2025

The time is now: making the case for compassionate use/pre-approval access to new TB drugs.

A Reuter, J Stillo, S S Thi, I Motta, G B Migliori, A Mesic, M Mbenga, P Howell, L Guglielmetti, A Gebhard and 3 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

A ReuterStellenbosch University, Stellenbosch, South Africa.
J StilloWayne State University, Detroit, MI, USA.
S S ThiNational TB Program, Mbabane, Eswatini.
I MottaMédecins Sans Frontières, Amsterdam, the Netherlands.
G B MiglioriIstituti Clinici Scientifici Maugeri, IRRCS, Tradate, Italy.
A MesicMédecins Sans Frontières, Amsterdam, the Netherlands.
M MbengaKNCV, The Hague, the Netherlands.
P HowellWits Health Consortium, University of the Witwatersrand, Johannesburg, South Africa.
L GuglielmettiDepartment of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy.
A GebhardKNCV, The Hague, the Netherlands.
T DeCrooInstitute for Tropical Medicine, Antwerp, Belgium.
L D'AmbrosioPublic Health Consulting Group, Lugano, Switzerland.
J FurinHarvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the majority of people with multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) can now be successfully treated with all-oral shorter regimens, rising rates of resistance to the components in these regimens are a growing global challenge. The drug development pipeline for TB has more novel compounds in phase 2 trials than ever before, and accessing these agents through systematic compassionate use programmes is an ethical and public health imperative. There is more than a decade of successful experience with compassionate use for MDR/RR-TB, resulting in benefits for people with MDR/RR-TB, novel chemical entity developers, providers, and programmes. Although there are some arguments for delaying access to the new TB drugs in the pipeline, we present reasons why such access should be an urgent priority for all TB stakeholders.

Indexed as

drug-resistant TBethicsnew drugstuberculosis

Identifiers

PMID41395317
PMCPMC12699964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.